---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010850"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:21:12.877956+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KALA BIO completes Phase 2b enrollment for KPI-012; cash runway into Q1 2026

## Summary
- Net loss $11.2M ($1.71/share) for Q2 2025 vs $9.6M ($3.16) in Q2 2024.
- Cash $31.9M as of June 30; expected to fund operations into Q1 2026.
- Phase 2b CHASE trial enrolled 79 patients; topline data expected end of September 2025.
- R&D expenses $6.2M in Q2, up 17% YoY due to KPI-012 development costs.
- Interim CEO says positive results could support a BLA submission to FDA.

## SEC filing metadata
- accession: 0001558370-25-010850
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/0001558370-25-010850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010850
- JSON: https://secwatch.observer/filing/0001558370-25-010850.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.